Time-dependent inhibition of CYP3A4 by gallic acid in human liver microsomes and recombinant systems

References

• Cartron E, Fouret G, Carbonneau MA, et al. (2003). Red-wine beneficial long-term effect on lipids but not on antioxidant characteristics in plasma in a study comparing three types of wine – description of two O-methylated derivatives of gallic acid in humans. Free Radic Res 37:1021–35
   PubMed Web of Science ®Google Scholar
• Crozier A, Jaganath IB, Clifford MN. (2009). Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 26:1001–43
   PubMed Web of Science ®Google Scholar
• Feng S, He X. (2013). Mechanism-based inhibition of CYP450: an indicator of drug-induced hepatotoxicity. Curr Drug Metab 14:921–45
   PubMed Web of Science ®Google Scholar
• Fujita K. (2004). Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 20:195–217
   PubMedGoogle Scholar
• Honig PK, Wortham DC, Zamani K, et al. (1993). Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513–8
   PubMed Web of Science ®Google Scholar
• Jin Y, Wang YH, Miao J, et al. (2007). Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 82:579–85
   PubMed Web of Science ®Google Scholar
• Kadono K, Koakutsu A, Naritomi Y, et al. (2014). Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method. Xenobiotica 44:511–21
   PubMed Web of Science ®Google Scholar
• Kamel A, Harriman S. (2013). Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI). Drug Discov Today Technol 10:e177–89
   PubMedGoogle Scholar
• Kitz R, Wilson IB. (1962). Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245–9
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Schuetz EG, Thummel KE. (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271–94
   PubMed Web of Science ®Google Scholar
• Li Z, Wang K, Zheng J, et al. (2014). Interactions of the active components of Punica granatum (pomegranate) with the essential renal and hepatic human Solute Carrier transporters. Pharm Biol 1–8 [Epub ahead of print]. doi:10.3109/13880209.2014.900809
   Web of Science ®Google Scholar
• Lin JH, Lu AY. (1998). Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35: 361–90
   PubMed Web of Science ®Google Scholar
• Manach C, Williamson G, Morand C, et al. (2005). Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81:230S–42S
   PubMed Web of Science ®Google Scholar
• McConn DJ 2nd, Lin YS, Allen K, et al. (2004). Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32:1083–91
   PubMed Web of Science ®Google Scholar
• Mouly SJ, Matheny C, Paine MF, et al. (2005). Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther 78:605–18
   PubMed Web of Science ®Google Scholar
• Perloff ES, Mason AK, Dehal SS, et al. (2009). Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 39:99–112
   PubMed Web of Science ®Google Scholar
• Roberts AT, Martin CK, Liu Z, et al. (2007). The safety and efficacy of a dietary herbal supplement and gallic acid for weight loss. J Med Food 10:184–8
   PubMed Web of Science ®Google Scholar
• Shahrzad S, Aoyagi K, Winter A, et al. (2001). Pharmacokinetics of gallic acid and its relative bioavailability from tea in healthy humans. J Nutr 131:1207–10
   PubMed Web of Science ®Google Scholar
• Shi L, Zhang YD, Wang EH, et al. (2014). Inhibitory effect of gallic acid and its oxidation products on CYP3A in rat liver microsomes. J Third Military Medical University 36:130–4
   Google Scholar
• Stupans I, Stretch G, Hayball P. (2000). Olive oil phenols inhibit human hepatic microsomal activity. J Nutr 130:2367–70
   PubMed Web of Science ®Google Scholar
• Stupans L, Tan HW, Kirlich A, et al. (2002). Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid. J Pharm Pharmacol 54:269–75
   PubMed Web of Science ®Google Scholar
• Tapaninen T, Neuvonen PJ, Niemi M. (2010). Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol 66:497–502
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol 38:389–430
   PubMed Web of Science ®Google Scholar
• Verma S, Singh A, Mishra A. (2013). Gallic acid: molecular rival of cancer. Environ Toxicol Pharmacol 35: 473–85
   PubMed Web of Science ®Google Scholar
• Wang L, Sweet DH. (2012). Potential for food-drug interactions by dietary phenolic acids on human organic anion transporters 1 (SLC22A6), 3 (SLC22A8), and 4 (SLC22A11). Biochem Pharmacol 84:1088–95
   PubMed Web of Science ®Google Scholar
• Yuan R, Madani S, Wei XX, et al. (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311–9
   PubMed Web of Science ®Google Scholar
• Yun CH, Okerholm RA, Guengerich FP. (1993). Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 21:403–9
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279–304
   PubMed Web of Science ®Google Scholar